
Yüksel Ürün/X
Apr 23, 2025, 06:34
Yüksel Ürün: DESTINY-Breast09 – Enhertu plus Pertuzumab Outperforms THP
Yüksel Ürün, Prof. Dr. Ankara University School of Medicine, Department of Medical Oncology, shared a post on X:
“DESTINY-Breast09 shows: Enhertu + Pertuzumab > THP
Significant PFS benefit.
Consistent across all subgroups.
Early OS trend favoring combo.
Is this anew era in 1st-line HER2+ met. Breast cancer?”
-
Challenging the Status Quo in Colorectal Cancer 2024
December 6-8, 2024
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023
Apr 23, 2025, 06:34
Apr 23, 2025, 06:24
Apr 23, 2025, 01:36
Apr 22, 2025, 19:24
Apr 22, 2025, 18:28
Apr 22, 2025, 17:31